Clinical Research Directory

Inclusion Criteria: * age 18-21 at eligibility visit * body mass index of 18.5-30 * report using cannabis ≥10 times in their life and ≥1 time in the past 3 months, but \<7 days a week (daily) * medically and neurologically healthy * score of ≥0.25 on the Personality Inventory for DSM-5 (PID-5) Anhedonia subscale Exclusion Criteria: * positive urine drug screen (UDS; except for THC) and/or positive saliva THC test * contraindication for fMRI BOLD study (e.g., metal implants) * severe mental illness (e.g., psychosis, mania, lifetime moderate-to-severe SUD (including moderate-to-severe CUD)) * heavy nicotine use in the past month (\>20 cigarettes per week or electronic nicotine delivery system (ENDS) use equivalent * night shift work * females who are currently pregnant confirmed by urine pregnancy test, are planning pregnancy, or are lactating * unwilling/unable to sign informed consent document * current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances (Dronabinol/Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide) * physical or neurological diagnoses (e.g., cancer, diabetes, seizure disorder, Parkinson's, Multiple Sclerosis, loss of consciousness \>10 min., etc.) that in the opinion of the Study Physician and Investigators could increase safety risks or influence the findings * currently taking any medication that could interact with a single dose of Δ9-THC